CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality Determinants and Impact of Heart Failure Readmission Following Transcatheter Aortic Valve Replacement Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week Impact of Incomplete Coronary Revascularization on Late Ischemic and Bleeding Events after Transcatheter Aortic Valve Replacement The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial 2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study

GuidelineJune 13, 2019

JOURNAL:JAMA Article Link

Primary Prevention of Sudden Cardiac Death

A D. Beaser; Adam S. Cifu, MD; Hemal M. Nayak. Keywords: rhythem dysorder; sudden cardiac death; primary prevention; LVEF; heart failure; ventricular fibrillation

ABSTRACT

Ventricular arrhythmias range from benign premature ventricular contractions to ventricular fibrillation and can be asymptomatic or have sudden cardiac death as the first manifestation. Sudden cardiac death is a major public health problem, accounting for 50% of all cardiovascular death.1 Although a plurality of sudden cardiac death occurs in the general population with no apparent cardiac risk factors, the risk is greatest in patients with LVEF of less than 30%, clinical heart failure, prior aborted cardiac arrest, or coronary artery disease.2